{"disease":{"id":"hormone-refractory-prostate-cancer","name":"Hormone refractory prostate cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"olaparib","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lynparza","generic_name":"olaparib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","quality_score":73,"revenue":"2600","mechanism":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP."},{"drug_id":"darolutamide","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"niraparib","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zejula","generic_name":"niraparib","company_name":"GSK","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 2","drug_class":"Poly(ADP-Ribose) Polymerase Inhibitor","quality_score":69,"revenue":"600","mechanism":"Zejula works by blocking the action of an enzyme called PARP, which helps repair damaged DNA in cancer cells."},{"drug_id":"mitoxantrone","indication_name":"Advanced Hormone-Refractory Prostate Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"lynparza","indication_name":"Hormone refractory prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lynparza","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00286091","title":"Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1435,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00699751","title":"A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":921,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05997615","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":390,"lead_sponsor_name":"Vir Biotechnology, Inc.","has_results":false},{"nct_id":"NCT02955082","title":"The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":305,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT02691975","title":"A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":197,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT00510718","title":"A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01419717","title":"Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT00477529","title":"ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT00667199","title":"BAY88-8223, Does Response Study in HRPC Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02288936","title":"Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Spanish Oncology Genito-Urinary Group","has_results":false},{"nct_id":"NCT03658434","title":"Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Zealand University Hospital","has_results":false},{"nct_id":"NCT04477512","title":"Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03076203","title":"Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT03861403","title":"A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Leap Therapeutics, Inc.","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}